Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers

Cancer Research

Volumn 60, Issue 14, 2000, Pages 3862-3871

  Sarkar, Somdatta ^a   Jülicher, Knut P ^a   Burger, Melissa S ^a   Valle, Véronique Della ^b   Larsen, Christian Jacques ^c   Yeager, Thomas R ^d   Grossman, Timothy B ^a   Nickells, Robert W ^a   Protzel, Chris ^a   Jarrard, David F ^a   Reznikoff, Catherine A ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b INSERM   (France)

^c Faculti des Sciences   (France)

^d CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; BLADDER CANCER; GAMMA IRRADIATION; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOSIS INHIBITION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

BLOTTING, NORTHERN; BLOTTING, SOUTHERN; CARCINOMA, TRANSITIONAL CELL; CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FLOW CYTOMETRY; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; PHENOTYPE; PROTEINS; RETINOBLASTOMA PROTEIN; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0034660870     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Overcoming cellular senescence in human cancer pathogenesis
2. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer
3. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents
4. Cell cycle control. DNA repair and initiation of carcinogenesis
5. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 ElA and accompanies apoptosis
6. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes
7. Involvement of the p53 tumor suppressor in repair of U.V.-type DNA damage
8. The p16INK4a/CDKN2A tumor suppressor and its relatives
9. Rates of p16 (MTS1) mutations in primary tumors with 9p loss
10. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors
11. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer
12. The 9p21 region in bladder cancer cell lines: Large homozygous deletion inactivate the CDKN2A, CDKN2B and MTAP genes
13. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer
14. Frequent somatic mutation of the MTSl/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma
15. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
16. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines
17. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
18. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
19. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
20. A cell cycle regulator potentially involved in genesis of many tumor types
21. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
22. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells
23. p16/pRb alterations are required for overcoming senescence in prostate epithelial cells
24. Regulation of p16/CDKN2 expression and its implications for cell immortalization and senescence
25. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts
26. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas
27. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression
28. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors
29. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers
30. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer
31. Function of a human cyclin gene as an oncogene
32. A p16INK4a insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
33. p53 mutations in human cancers
34. The p53 tumor suppressor gene
35. Analysis of p21WAF1/ClPl in primary bladder tumors
36. Effect of p21WAF1/ClPl expression on tumor progression in bladder cancer
37. Amplification of a gene encoding a p53-associated protein in human sarcomas
38. Mdm2 promotes the rapid degradation of p53
39. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
40. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein
41. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway
42. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma
43. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein
44. A new type of p16/INK4a/MTS1 gene transcript expressed in B-cell malignancies
45. Splicing into senescence: The curious case of p16 and p19ARF
46. A novel p16INK4A transcript
47. Complex structure and regulation of the p16 (MTS1) locus
48. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
49. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2
50. ARF
51. p14ARF links the tumour suppressors RB and p53
52. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down regulated by wild-type p53
53. The Ink4a tumor suppressor gene product, p19, interacts with MDM2 and neutralizes MDM2's inhibition of p53
54. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both Rb and p53 tumor suppression pathways
55. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
56. E1A signaling to p53 involves the p19(ARF) tumor suppressor
57. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens
58. Mediation of c-Myc-induced apoptosis by p53
59. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2
60. An in vitro model for human bladder cancer pathogenesis studies
61. The human protein p19ARF is not detected in hemopoietic human cell lines that abundantly express the alternative β transcript of the p16INK4a/MTS1
62. A biomarker that identifies senescent human cells in culture and in aging skin in vivo
63. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia
64. Biochemical and molecular carcinogenesis
65. The role of DNA methylation in expression of the p16/p19 locus in human bladder cancer cell lines
66. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53
67. p53 and RB expression predict progression in T1 bladder cancer
68. Altered retinoblastoma protein expression and prognosis in early-stage non-small cell lung carcinoma
69. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: Potential synergistic effects on prognosis
70. Tumorigenic effects of germline mutations in Rb and p53